Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Akums Drugs & Pharma acquires new formulation facility in Baddi

Ruchika Sharma6 Dec 2023 4:30 PM IST

Himachal Pradesh: Akums Drugs & Pharmaceuticals has said it has acquired a new formulation facility located in Baddi, Himachal Pradesh.The plant,...

Zydus Lifesciences gets USFDA okay for acquired methemoglobinemia injection Methylene Blue

Ruchika Sharma6 Dec 2023 3:30 PM IST

Methylene Blue Injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.

Natco Pharma gets 7 USFDA observations for Kothur Pharma Division

Sun Pharma, Torrent Pharma and 2 others undergoing USFDA inspections

Ruchika Sharma6 Dec 2023 2:30 PM IST

Hyderabad: The U.S. Food and Drug Administration is inspecting Dr Reddy's research and development centre in the southern Indian city of...

Zydus Lifesciences Told To Revise PMS Study For Tofacitinib ER Tablets

Zydus Lifesciences US arm concludes asset transfer of CUTX-101 for Menkes disease from Cyprium Therapeutics

Ruchika Sharma6 Dec 2023 1:30 PM IST

Sentynl now assumes full responsibility for the development and commercialization of CUTX-101.

CDSCO Panel Denies Trial Waiver for Atropine, Asks Sun Pharma to Conduct Phase III Study

Sun Pharma arm signs licensing agreement with Aclaris Therapeutics

Ruchika Sharma6 Dec 2023 12:30 PM IST

The agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties.

Lupin Nagpur facility completes USFDA inspection

Lupin bags USFDA nod for Varenicline Tablets for smoking cessation treatment

Ruchika Sharma6 Dec 2023 11:30 AM IST

Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.

Aspen Pharmacare to buy Chinese business of Sandoz for USD 100.6 million

Ruchika Sharma5 Dec 2023 4:50 PM IST

Additionally, Aspen will dispose of the commercialisation rights and related intellectual property for four anaesthetic products currently sold by...

Eli Lilly joins trillion-dollar club, fueled by weight loss drug demand boom

Eli Lilly extends tender offer to acquire POINT Biopharma to 15 Dec

Ruchika Sharma5 Dec 2023 2:45 PM IST

Indianapolis: Eli Lilly and Company has announced the extension of the expiration of the tender offer to acquire all of the issued and...

Roche unveils new PCR test to improve Vaginitis Diagnosis in countries following CE Mark

Roche joins race for obesity drugs with USD 2.7 billion Carmot deal

Ruchika Sharma5 Dec 2023 1:30 PM IST

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to...

Pradeep Chakravarty joins Alembic Pharma as Head - Global Quality

Ruchika Sharma5 Dec 2023 12:27 PM IST

Vadodara: Alembic Pharma has announced that Pradeep Chakravarty has joined the Company w.e.f. 4th December, 2023, as Head - Global Quality (Senior...

USFDA nod to JnJ Tremfya for Crohns disease

JnJ gets USFDA breakthrough therapy designation for TAR 200 for bladder cancer treatment

Ruchika Sharma5 Dec 2023 11:27 AM IST

TAR-200 is a novel investigational targeted releasing system designed to provide sustained local release of gemcitabine into the bladder.

AstraZeneca discontinues 2 Phase III evidence trials for Lokelma

Ruchika Sharma4 Dec 2023 4:00 PM IST

The decision to discontinue the trials is not due to safety concerns and the positive benefit-risk of Lokelma does not change in the approved...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok